{"url_path":"/sec/srts/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1494891/0001753926-26-000845-index.html","accession_number":"0001753926-26-000845","cik":"0001494891","ticker":"SRTS","issuer_name":"Sensus Healthcare, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1494891/0001753926-26-000845-index.html","primary_entity_key":"0001494891","primary_entity_name":"Sensus Healthcare, Inc."},"word_count":268,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\n*(a) Termination of Credit Facility*\n\n \n\nOn May 8, 2026, the Company received notice\nfrom Fifth Third that the Credit Facility will terminate effective as of May 20, 2026. At March 31, 2026 and December 31, 2025,\nthe Company was in default under the Credit Facility for failing to maintain the required minimum profitability covenant. There\nwere no borrowings outstanding under the facility at March 31, 2026 and December 31, 2025.\n\n  \n\nSee Note 3, *Debt*, to the condensed\nconsolidated financial statements for more information, including a summary of the material terms and conditions of the Credit\nFacility. Such summary is qualified in its entirety by reference to the agreements underlying the Credit Facility: the Credit Agreement,\nMaster Revolving Note, and Security Agreement, which were filed as Exhibits 10.1, 10.2, and 10.3 to the Company’s Current\nReport on Form 8-K filed with the SEC on September 14, 2023, and the Amendment No. 1 to the Credit Agreement and Amendment No.\n1 to the Master Revolving Note, which were filed as Exhibits 10.1 and 10.2 to the Company's Quarterly Report on Form 10-Q filed\nwith the SEC on November 14, 2024.\n\n \n\n*(c)\nRule 10b5-1 Trading Plans*\n\n \n\nDuring\nthe three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)\nadopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to\nsatisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement”\nas defined in Item 408(c) of Regulation S-K.\n\n \n\n28"}